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P.R.van.Dijk@isala.nlAbstractIn type 1 diabetes mellitus (T1DM), low concentrations of IGF1 and high concentrations of
IGF-binding protein 1 (IGFBP1) have been reported. It has been suggested that these
abnormalities in the GH–IGF1 axis are due to low insulin concentrations in the portal vein.
We hypothesized that the i.p. route of insulin administration increases IGF1 concentrations
when compared with the s.c. route of insulin administration. IGF1 and IGFBP1 concentrations
in samples derived from an open-label, randomized cross-over trial comparing the effects of
s.c. and i.p. insulin delivery on glycaemia were determined. T1DM patients were randomized
to receive either 6 months of continuous i.p. insulin infusion (CIPII) through an implantable
pump (MIP 2007C, Medtronic) followed by 6 months of s.c. insulin infusion or vice versa with
a washout phase in between. Data from 16 patients who had complete measurements
during both treatment phases were analysed. The change in IGF1 concentrations during CIPII
treatment was 10.4 mg/l (95% CIK0.94, 21.7 mg/l; PZ0.06) and during s.c. insulin treatment
wasK2.2 mg/l (95% CIK13.5, 9.2 mg/l; PZ0.69). When taking the effect of treatment order
into account, the estimated change in IGF1 concentrations was found to be 12.6 mg/l (95% CI
K3.1, 28.5 mg/l; PZ0.11) with CIPII treatment compared with that with s.c. insulin treatment.
IGFBP1 concentrations decreased toK100.7 mg/l (95% CIK143.0,K58.3 mg/l; P!0.01) with
CIPII treatment. During CIPII treatment, parts of the GH–IGF1 axis changed compared with
that observed during s.c. insulin treatment. This supports the hypothesis that the i.p. route of
insulin administration is of importance in the IGF1 system.Key Words
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.0 UEndocrine Connections
(2014) 3, 17–23IntroductionInsulin and insulin-like growth factor 1 (IGF1) are
structurally and functionally closely related peptides.
IGF1, mainly synthesized in the liver after stimulation of
the GH receptor, plays a central role in cell metabolism
and growth regulation (1, 2, 3). In plasma, IGF1 is bound
to IGF-binding proteins (IGFBPs), among which IGFBP3binds tow80% of the total amount of IGF1 present in the
circulation. It is only the free fraction of IGF1, comprising
!1% of the circulating IGF1, that is biologically active.
IGFBP1 is produced in the liver and regulated acutely (in
an inverse direction) by insulin, thereby allowing insulin
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2–7 3 :18Through an up-regulation of hepatic GH receptor
expression, insulin increases the hepatic sensitivity of GH
stimulation and subsequently increases IGF1 production
(8). Furthermore, insulin increases IGF1 bioactivity by a
down-regulation of IGFBP1 expression in the liver (5). In
type 1 diabetes mellitus (T1DM), with insufficient insuli-
nization of the liver due to lack of endogenous insulin in
the portal vein, there appears to be a dysfunction of the
GH–IGF1 axis. This is characterized by low concentrations
of total IGF1 and IGFBP3 and high concentrations of
IGFBP1 and GH (9, 10, 11, 12, 13, 14). Although these
abnormalities have been described in a situation of poor
glycaemic control, exogenous s.c. insulin only attenuates
these disturbances but does not completely reverse them
(15, 16, 17, 18).
With continuous i.p. insulin infusion (CIPII), insulin
is infused directly into the i.p. space and is almost entirely
absorbed in the portal system, resulting in higher portal
insulin concentrations, higher hepatic uptake and lower
peripheral plasma insulin concentrations compared with
those observed upon s.c. insulin administration (19, 20).
This results in a more physiological mode of insulin
administration compared with s.c. insulin administration
and could thus have a beneficial effect on the impaired
GH–IGF1 axis (21). In this study, we tested the hypothesis
that intraperitoneally administered insulin when
compared with s.c. insulin results in an increase in IGF1
concentrations in samples derived from a randomized
cross-over trial (Supplementary Figures 1, 2, and 3,
see section on supplementary data given at the end of
this article).Subjects and methods
Study design and population
The full study design has been published previously (22).
In brief, the study from which the samples were derived
had an open-label randomized, cross-over design and
was conducted at a single centre (Isala Clinics, Zwolle,
The Netherlands). The study consisted of four phases:
the qualification phase, the first treatment phase, the
cross-over phase and the second treatment phase. During a
3-month qualification phase, the patients’ prestudy
insulin therapy was used to attempt optimization
of their glycaemic control. Patients with T1DM (aged
18–70 years with fasting C-peptide concentrations
!0.20 nmol/l, HbA1c concentrations R58 mmol/mol
and/or R5 incidents of hypoglycaemia (!4.0 mmol/l)
per week and treated with multiple daily injections (MDIs)http://www.endocrineconnections.org
DOI: 10.1530/EC-13-0089
 2014 The authors
Published by Bioscientifica Ltdor continuous s.c. insulin infusion (CSII)) were randomly
allocated to continue their current s.c. mode of therapy or
start with i.p. insulin administration using an implantable
pump. These two groups (start i.p. or continue s.c.)
differed only in the sequence of the mode of insulin
administration. Randomization was carried out using
sealed non-transparent envelopes, with adequate blinding
of the content of the envelopes. The patients were
assigned to the treatment order as defined by the code in
the envelopes (start i.p. or continue s.c.). The randomiz-
ation system used blocks of 4. In the original study, 50
patients were screened for eligibility, of which 25 entered
the qualification phase. In one patient, acceptable
glycaemic control was reached during the qualification
phase and thus 24 patients were randomly assigned to the
first treatment phase; 12 patients were assigned to
continue s.c. insulin and 12 patients to start with CIPII
during the first phase of the trial. One patient, with CIPII
at start, withdrew consent during the trial. In the present
analysis, we included only patients with complete IGF1
results in both treatment phases; therefore, seven patients
were excluded.
Insulin (U400 semi-synthetic human insulin of
porcine origin; Hoechst, Frankfurt, Germany, nowadays
Sanofi-Aventis) was administered with an implantable
pump (MIP 2007C; Medtronic/Minimed, Northridge, CA,
USA). The CIPII pump was implanted under general
anaesthesia at the start of the CIPII phase in all the
subjects. For subjects who received s.c. insulin during the
second treatment phase, the CIPII pump was filled with an
inert fluid at the end of the first treatment phase.
S.c. insulin was delivered with either MDIs or CSII,
according to what was used before the study.
Patients treated with MDIs continued to follow their
own insulin regimen, i.e. rapid-acting insulin analogues
before meals and a daily dose of long-acting insulin.
Between both treatment phases of 6 months, a cross-over
phase of 4 weeks was instituted to minimize the carry-over
effects of CIPII treatment. During the cross-over phase,
insulin was administered subcutaneously.
If the subject was using more than 40 IU of s.c. insulin
per day before starting the CIPII phase of the study, his or
her starting dose was set at 90% of the prior s.c. dose.
Subjects using !40 IU of s.c. insulin received a starting
dose of 80% of the prior s.c. dose. Initially, the dose was
equally divided between a basal rate (50%) and a bolus
before meals. During all study visits, the seven-point
glucose readings were used to adjust the dose regimen if
necessary to achieve preprandial glucose levels between
4.0 and 7.0 mmol/l and postprandial levels betweenThis work is licensed under a Creative Commons
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3–7 3 :194.0 and 9.0 mmol/l. The patients were instructed not to
start a specific diet or weight reduction programme during
the trial.Measurements of clinical and biochemical parameters
Measurements were carried out at baseline, the end of
the qualification phase, and at the start, at the halfway
point, and at the end of both treatment phases. HbA1c
concentrations weremeasured using a Primus Ultra2 using
HPLC (reference value 20–42 mmol/mol). IGF1 and
IGFBP1 concentrations, reported as mg/l, were measured
in 1.5 cc serum samples collected at random and non-
fasting at the start and end of each treatment phase and
stored atK80 8C until analysis in 2011, carried out at the
Department of Clinical and Experimental Medicine of the
Linko¨ping University, Linko¨ping, Sweden. Total IGF1
concentration was measured using a one-step ELISA after
acid–ethanol extraction from its binding protein using a
commercial kit (Human IGFI Quantikine ELISA Kit R&D
Systems) (23). Inter-assay coefficients of variation (CV)
values were 10.9, 5.9 and 18.2% for high (278 mg/l),
medium (116 mg/l) and low (45 mg/l) controls respectively.
IGFBP1 concentration was measured with ELISA (human
IGFBP1 DuoSet, DY871, R&D Systems, Minneapolis, MN,
USA). The assay was carried out according to the protocol
provided by themanufacturer. Microtiter plates, MaxiSorp
(Nunc, Roskilde, Denmark), normal goat serum (Fisher
Scientific) and tetramethylbenzidine dihydrochloride
(Sigma Life Science) were used. The microtiter plates
were coated overnight with capture antibody. Inter-assay
CV values for high (1688 mg/l) and low (4 mg/l) controls
were 7.8 and 20.0% respectively.Primary and secondary outcomes
The primary outcome of this post hoc analysis was the
difference in IGF1 concentrations between the two treat-
ment phases. Secondary outcomes were changes in IGFBP1
concentrations during both treatment phases, changes in
IGF1 and IGFBP1 concentrations in patients with and
without detectable C-peptide and correlations of changes
in HbA1c concentrations, total insulin dose, C-peptide
concentrations with IGF1 and IGFBP1 concentrations.Statistical analyses
To calculate the mean difference with a 95% CI, the Hills–
Armitage approach was used, which accounts for any
period effect. Linear mixed models (PROC MIXED, SAS
9.2; SAS Institute Inc, Cary, NC, USA) were used to testhttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0089
 2014 The authors
Published by Bioscientifica Ltddifferences, taking treatment order into account. The
assumption of normal distribution of the residuals was
examinedusingQ–Q plots. In addition,Q–Q plotswere used
to determine whether the tested variable had a normal
distribution. Correlations were investigated using the
Pearson product–moment correlation coefficient or, when
appropriate, non-parametric Spearman’s r. Comparisons
between outcomes during both treatment modalities were
made using t-test for paired comparisons for IGF1 and
Wilcoxonmatch-pair signed-rank tests for IGFBP1. Patients
with andwithout detectable C-peptidewere comparedwith
unpaired t-test. IGFBP1 concentrations had a skewed
distribution (right tail), and they are presented as median
and interquartile range (IQR). Differences in IGFBP1
concentrations were normally distributed. Besides the
linear mixed models, all the analyses were carried out
using SPSS version 18.0, Inc. A (two-sided) P value of!0.05
was considered to be statistically significant.Ethical considerations
The study was carried out in accordance with the
Declaration of Helsinki. Informed consent was obtained
from all the patients for the initial study. The protocol was
approved by the Medical Ethics Committee of the Isala
Clinics in Zwolle. Additional informed consent was
obtained for the present study.Results
Patients
The study sample consisted of 16 patients, six males and
ten females, with a median (IQR) age of 42.4 (30.4–49.4)
years and diabetes for a duration of 21.7 (10.4–30.5) years.
Three patients usedMDIs and 13 CSII before the study, the
qualification phase and the s.c. treatment phase. Mean
IGF1 (GS.D.) concentrations at the start of the s.c. and i.p.
insulin treatment phases were respectively 83.7G31.9 and
76.3G24.5 mg/l.IGF1 and IGFBP1 concentrations
Results obtained for the IGF1 and IGFBP1 measurements
during the different treatment modalities are summarized
in Table 1 and Fig. 1. The observed IGF1 and IGFBP1
concentrations were significantly different between both
treatment modalities at 3 and 6 months. No significant
carry-over effects were observed for IGF1 (PZ0.33) and
IGFBP1 (PZ0.83) concentrations between both treatment
phases.This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
Table 1 Observed IGF1, IGFBP1 and HbA1c concentrations and estimated changes during s.c. and i.p. insulin treatment. IGF1 and
HbA1c concentrations are presented as mean (S.D.) and IGFBP1 concentrations are presented as median (IQR). nZ16 for IGF1, IGFBP1
and HbA1c at all time points.
IGF1 (mg/l) IGFBP1 (mg/l) HbA1c (mmol/mol)
CIPII SC CIPII SC CIPII SC
0 monthsa 83.7 (31.9) 76.3 (24.5) 68.0 (35.3, 213.6) 19.7 (11.9, 52.0)* 68 (16.5) 68 (15.4)
3 months 96.1 (44.9) 74.4 (28.0)* 8.5 (5.8, 14.4) 25.5 (9.5, 45.5)* 60 (6.6) 70 (14.3)*













*P!0.05 for CIPII vs SC at that time point.
a0 months: at the end of the 3-month qualification phase.
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4–7 3 :20The estimated mean change in IGF1 concentrations
during the CIPII phase was 10.4 mg/l (95% CI K0.94,
21.7 mg/l; PZ0.06) and during the s.c. treatment phase was
K2.2 mg/l (95% CIK13.5, 9.2 mg/l; PZ0.69). When taking
the effect of treatment order into account, the estimated
difference in concentrations between the i.p. treatment
phase and the s.c. treatment phase was found to be
12.6 mg/l (95% CIK3.1, 28.5 mg/l; PZ0.11).
IGFBP1 concentrations decreased significantly during
the i.p. treatment phase, K100.7 mg/l (95% CI K143.0,
K58.3 mg/l; P!0.01), but not during the s.c. treatment
phase, 9.4 mg/l (95% CI K33.0, 51.8 mg/l; PZ0.64). The
estimated difference between both phases wasK110.4 mg/l























HbA1c concentrations decreased with CIPII treatment
from 68G16.5 to 60G6.6 mmol/mol after 3 months and
remained stable at 6 months (61G9.9 mmol/mol). During
the s.c. treatment phase, there was no change in glycaemic
control. No significant carry-over effects were observed
between both treatment phases (PZ0.05). HbA1c concen-
trations improved to K10.0 mmol/mol (95% CI K18.4,
K1.6; PZ0.02) with CIPII treatment than with s.c. insulin
treatment. During the i.p. treatment phase, changes in
HbA1c concentrations correlated with changes in IGF1
concentrations (rZK0.5, PZ0.04), but not with those in





Course of mean IGF1 (consecutive line) and median IGFBP1 (dashed line)
concentrations during 6 months of s.c. (red line) or i.p. (blue line) insulin
treatment.Total insulin dose, C-peptide concentrations and
associations with IGF1 and IGFPBP1 concentrations
Mean daily insulin dose decreased with i.p. treatment
with K2.0 IU/day (95% CI K13.7, 9.6 IU/day; PZ0.71)http://www.endocrineconnections.org
DOI: 10.1530/EC-13-0089
 2014 The authors
Published by Bioscientifica Ltdcompared with s.c. insulin treatment. Spearman’s corre-
lation coefficient indicated a non-significant association
between the mean difference in insulin dose and IGF1
concentrations during the i.p. treatment phase (rZK0.02,
PZ0.95). Changes in IGFBP1 concentrations did not
correlate with changes in total insulin dose (rZ0.19,
PZ0.48) during the i.p. treatment phase. Changes in IGF1
and IGFBP1 concentrations during the CIPII phase did not
exhibit any significant correlation (rZK0.23, PZ0.40).
There was no significant difference in the change in
IGF1 concentrations during the i.p. treatment phase
between patients with undetectable (%0.01 nmol/l, nZ6)
and detectable (O0.01 nmol/l, nZ10) C-peptide: 12.6G
22.2 vs 3.7G22.1 ng/ml (PZ0.45). IGFBP1 concentrations
wereK49.5 (K222.9,K17.4) andK57.7 (K182.7,K12.3)
mg/l respectively. The association between the concen-
trations of C-peptide and the change in IGF1 concen-
trations during the i.p. or s.c. treatment phase was also not
significant: rZK0.02 (PZ0.94) and rZK0.16 (PZ0.56).This work is licensed under a Creative Commons
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5–7 3 :21Discussion
Concentrations of IGFBP1 decreased significantly during
CIPII treatment compared to s.c. treatment. IGF1 concen-
trations did not change significantly during the i.p.
treatment phase, and this change was also not significant
when compared with that observed during intensive s.c.
insulin treatment.
As there is (almost) no insulin production in patients
with T1DM, it has been hypothesized that low insulin
concentrations in the portal vein cause decreased IGF1
concentrations/bioactivity through both GH receptor-
and IGFBP1-mediated mechanisms (5, 8). In all three
studies of the IGF system in which subjects with T1DM
were treated with i.p. insulin infusion, an increase in IGF1
concentrations was observed. Shishko et al. reported the
normalization of plasma IGF1 concentrations with intra-
portal infusion of insulin in newly diagnosed T1DM
patients (18). Unfortunately, that study lacked data
regarding the presence or absence of endogenous pro-
duction of insulin. A longitudinal study carried out by
Hanaire-Broutin et al. (18) demonstrated a steady increase
in plasma IGF1 concentrations to a low-normal level 1
year after the initiation of CIPII treatment, despite a lack of
improvement in HbA1c concentrations. In the present
study, IGF1 concentrations were significantly higher after
3 and 6months with CIPII treatment compared with those
observed with s.c. insulin treatment and a non-significant
change of 10.4 mg/l was observed within the i.p. treatment
period of 6 months. Compared with that observed during
s.c. insulin treatment, this change was not significant.
These findingsmay be due to the size of the sample (nZ16)
and/or the duration of the present study. In the study
carried out by Hanaire-Broutin, IGF1 concentrations
tended to increase even after 6 months. In severely
uncontrolled diabetes, IGF1 concentrations are low (24),
but ordinary glycaemic control probably has little effect on
IGF1 concentrations, as suggested by this study and shown
by Hedman et al. (17) earlier.
At the start of the CIPII treatment phase, several
patients had very high IGFBP1 values. Due to these
outliers, the IGFBP1 concentrations at the start of the
i.p. treatment phase were high. Of interest, all five patients
with IGFBP1 concentrations O150 mg/l (range: 181.2–
330.0 mg/l) were in the ‘i.p. first’ cross-over group. It was
remarkable that additional analysis indicated a signi-
ficantly longer median duration between pump implan-
tation and IGFBP1 measurement for these five patients
compared with the other patients (0.5 vs 0.0 years;
P!0.001). Therefore, we hypothesize that the highhttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0089
 2014 The authors
Published by Bioscientifica LtdIGFBP1 concentrations in these five individuals represent
an acute effect in the start-up phase of i.p. insulin. It has
been reported that insulin withdrawal for 8 h in patients
with type 1 diabetes treated with CSII increased IGFBP1
concentrations sixfold, and it is conceivable that the high
IGFBP1 values could be due to a lag in insulin delivery (4).
Nevertheless, post hoc analysis of patients with IGFBP1
concentrations !150 mg/l still indicated that the change
in IGFBP1 concentrations during the i.p. treatment phase
remained significant (K46.3 mg/l, 95% CI K80.2,
K12.4 mg/l; PZ0.01) and, as a right skew could influence
the estimated difference between the treatment modal-
ities, that the estimated difference between the treatment
groups still remained at K49.9 mg/l (95% CI K97.9,
K1.92 mg/l; PZ0.04). When paired comparisons of
IGFBP1 concentrations were made during treatment at
3 and 6 months, IGFBP1 concentrations were found to be
lower with CIPII treatment than with CSII treatment.
The lowering of IGFBP1 concentrations suggests an
increase in free IGF1 concentrations, i.e. IGF1 bioactivity
by CIPII treatment (1). As there was no increase in insulin
dose, this is compatible with an enhanced insulin effect on
the liver by CIPII treatment (3). The observed decrease in
IGFBP1 concentrations in the present study is in line with
previous reports and, as IGFBP1 concentrations correlate
with GH secretion and hepatic glucose production, may
indicate the importance of the i.p. route of insulin
administration (25, 26, 27).
For the interpretation of the results of this study, it
must be acknowledged that the original study was
powered to detect differences in hypoglycaemic events
between i.p. and s.c. insulin and not in IGF1 or IGFBP1
concentrations. In contrast to the studies carried out by
Shishko and Hanaire-Broutin (18, 25), samples were
collected randomly and information about the antecedent
insulin dose was lacking . Finally, lack of a large reference
population impairs the comparison of the IGF1
concentrations found in the present study with those of
healthy subjects.
Although the clinical significance of low IGF1
concentrations in patients with T1DM remains unclear
at present, CIPII could have an additional benefit on top of
glycaemic control by altering the dysregulated GH–IGF
system by increasing portal insulin concentrations. This is
a hypothesis worth testing in future research.Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
EC-13-0089.This work is licensed under a Creative Commons

















Research P R van Dijk et al. Effect of i.p. insulin on IGF1
and IGFBP1
6–7 3 :22Declaration of interest
The authors declare that there is no conflict of interest that could be
perceived as prejudicing the impartiality of the research reported.Funding
This research did not receive any specific grant from any funding agency in
the public, commercial or not-for-profit sector.Author contributions
P v D was responsible for study design and drafting and reviewing the
manuscript and carried out the statistical analyses; S L was responsible for
study design, inclusion, and drafting and reviewing the manuscript; N K
and H B were responsible for study design and reviewed the manuscript,
K G carried out the statistical analyses and reviewed the manuscript; and
H A was responsible for drafting and reviewing the manuscript.References
1 Frystyk J. Free insulin-like growth factors – measurements and
relationships to growth hormone secretion and glucose homeostasis.
Growth Hormone & IGF Research 2004 14 337–375. (doi:10.1016/j.ghir.
2004.06.001)
2 LeRoith D & Yakar S. Mechanisms of disease: metabolic effects of
growth hormone and insulin-like growth factor 1. Nature Clinical
Practice. Endocrinology & Metabolism 2007 3 302–310. (doi:10.1038/
ncpendmet0427)
3 Kim JJ & Accili D. Signalling through IGF-I and insulin receptors: where
is the specificity? Growth Hormone & IGF Research 2002 12 84–90.
(doi:10.1054/ghir.2002.0265)
4 Attia N, Caprio S, Jones TW, Heptulla R, Holcombe J, Silver D,
Sherwin RS & Tamborlane WV. Changes in free insulin-like growth
factor-1 and leptin concentrations during acute metabolic decom-
pensation in insulin withdrawn patients with type 1 diabetes. Journal of
Clinical Endocrinology and Metabolism 1999 84 2324–2328. (doi:10.1210/
jc.84.7.2324)
5 Brismar K, Fernqvist-Forbes E, Wahren J & Hall K. Effect of insulin on
the hepatic production of insulin-like growth factor-binding protein-1
(IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. Journal of
Clinical Endocrinology and Metabolism 1994 79 872–878. (doi:10.1210/jc.
79.3.872)
6 Suikkari AM, Koivisto VA, Rutanen EM, Yki-Ja¨rvinen H, Karonen SL &
Seppa¨la¨ M. Insulin regulates the serum levels of low molecular weight
insulin-like growth factor-binding protein. Journal of Endocrinology and
Metabolism 1988 66 266–272. (doi:10.1210/jcem-66-2-266)
7 Orlowski CC, Ooi GT, Brown DR, Yang YW, Tseng LY & Rechler MM.
Insulin rapidly inhibits insulin-like growth factor-binding protein-1
gene expression in H4-II-E rat hepatoma cells. Molecular Endocrinology
1991 5 1180–1187. (doi:10.1210/mend-5-8-1180)
8 Leung KC, Doyle N, Ballesteros M, Waters MJ & Ho KK. Insulin
regulation of human hepatic growth hormone receptors: divergent
effects on biosynthesis and surface translocation. Journal of Clinical
Endocrinology and Metabolism 2000 85 4712–4720. (doi:10.1210/jc.85.
12.4712)
9 Hansen AP & Johansen K. Diurnal patterns of blood glucose, serum free
fatty acids, insulin, glucagon and growth hormone in normals and
juvenile diabetics. Diabetologia 1970 6 27–33. (doi:10.1007/
BF00425888)
10 Merimee TJ, Gardner DF, Zapf J & Froesch ER. Effect of glycemic control
on serum insulin-like growth factors in diabetes mellitus. Diabetes 1984
33 790–793. (doi:10.2337/diab.33.8.790)http://www.endocrineconnections.org
DOI: 10.1530/EC-13-0089
 2014 The authors
Published by Bioscientifica Ltd11 Amiel SA, Sherwin RS, Hintz RL, Gertner JM, Press CM &
Tamborlane WV. Effect of diabetes and its control on insulin-like
growth factors in the young subject with type I diabetes. Diabetes 1984
33 1175–1179. (doi:10.2337/diab.33.12.1175)
12 Tan K & Baxter RC. Serum insulin-like growth factor I levels in adult
diabetic patients: the effect of age. Journal of Clinical Endocrinology and
Metabolism 1986 63 651–655. (doi:10.1210/jcem-63-3-651)
13 Jehle PM, Jehle DR, Mohan S & Bo¨hm BO. Serum levels of insulin-like
growth factor system components and relationship to bone metab-
olism in type 1 and type 2 diabetes mellitus patients. Journal of
Endocrinology 1998 159 297–306. (doi:10.1677/joe.0.1590297)
14 Bereket A, Lang CH & Wilson TA. Alterations in the growth hormone-
insulin-like growth factor axis in insulin dependent diabetes mellitus.
Hormone and Metabolic Research 1999 31 172–181. (doi:10.1055/s-2007-
978716)
15 Ekman B, Nystro¨m F & Arnqvist HJ. Circulating IGF-I concentrations
are low and not correlated to glycaemic control in adults with type 1
diabetes. European Journal of Endocrinology / European Federation of
Endocrine Societies 2000 143 505–510. (doi:10.1530/eje.0.1430505)
16 Hedman CA, Orre-Pettersson AC, Lindstro¨m T & Arnqvist HJ. Treat-
ment with insulin lispro changes the insulin profile but does not affect
the plasma concentrations of IGF-I and IGFBP-1 in type 1 diabetes.
Clinical Endocrinology 2001 55 107–112. (doi:10.1046/j.1365-2265.
2001.01327.x)
17 Hedman CA, Frystyk J, Lindstro¨m T, Chen J-W, Flyvbjerg A, Orskov H&
Arnqvist HJ. Residual b-cell function more than glycemic control
determines abnormalities of the insulin-like growth factor system in
type 1 diabetes. Journal of Clinical Endocrinology and Metabolism 2004 89
6305–6639. (doi:10.1210/jc.2004-0572)
18 Hanaire-Broutin H, Sallerin-Caute B, Poncet MF, Tauber M, Bastide R,
Rosenfeld R & Tauber JP. Insulin therapy and GH-IGF-I axis disorders in
diabetes: impact of glycaemic control and hepatic insulinization.
Diabetes & Metabolism 1996 22 245–250.
19 Nathan DM, Dunn FL, Bruch J, McKitrick C, Larkin M, Haggan C,
Lavin-Tompkins J, Norman D, Rogers D & Simon D. Postprandial
insulin profiles with implantable pump therapy may explain decreased
frequency of severe hypoglycemia, compared with intensive subcu-
taneous regimens, in insulin-dependent diabetes mellitus patients.
American Journal of Medicine 1996 100 412–417. (doi:10.1016/S0002-
9343(97)89516-2)
20 Selam JL, Bergman RN, Raccah D, Jean-Didier N, Lozano J &
Charles MA. Determination of portal insulin absorption from perito-
neum via novel nonisotopic method. Diabetes 1990 39 1361–1365.
(doi:10.2337/diab.39.11.1361)
21 Schade DS, Eaton RP, Davis T, Akiya F, Phinney E, Kubica R, Vaughn EA
& Day PW. The kinetics of peritoneal insulin absorption. Metabolism
1981 30 149–155. (doi:10.1016/0026-0495(81)90164-5)
22 Logtenberg SJ, Kleefstra N, Houweling ST, Groenier KH, Gans RO, van
Ballegooie E & Bilo HJ. Improved glycemic control with intraperitoneal
versus subcutaneous insulin in type 1 diabetes: a randomized
controlled trial. Diabetes Care 2009 32 1372–1377. (doi:10.2337/
dc08-2340)
23 Andreassen M, Nielsen K, Raymond I, Kristensen LØ & Faber J.
Characteristics and reference ranges of Insulin-Like Growth Factor-I
measured with a commercially available immunoassay in 724
healthy adult Caucasians. Scandinavian Journal of Clinical and
Laboratory Investigation 2009 69 880–885. (doi:10.3109/
00365510903165477)
24 Rieu M & Binoux M. Serum levels of insulin-like growth factor (IGF)
and IGF binding protein in insulin-dependent diabetics during an
episode of severe metabolic decompensation and the recovery phase.
Journal of Clinical Endocrinology and Metabolism 1985 60 781–785.
(doi:10.1210/jcem-60-4-781)
25 Shishko PI, Dreval AV, Abugova IA, Zajarny IU & Goncharov VC.
Insulin-like growth factors and binding proteins in patients with
recent-onset type 1 (insulin-dependent) diabetes mellitus: influence ofThis work is licensed under a Creative Commons

















Research P R van Dijk et al. Effect of i.p. insulin on IGF1
and IGFBP1
7–7 3 :23diabetes control and intraportal insulin infusion. Diabetes Research and
Clinical Practice 1994 25 1–12. (doi:10.1016/0168-8227(94)90155-4)
26 Hilding A, Brismar K, Degerblad M, Thore´n M&Hall K. Altered relation
between circulating levels of insulin-like growth factor-binding
protein-1 and insulin in growth hormone-deficient patients and
insulin-dependent diabetic patients compared to that in healthyhttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0089
 2014 The authors
Published by Bioscientifica Ltdsubjects. Journal of Clinical Endocrinology and Metabolism 1995 80
2646–2652. (doi:10.1210/jc.80.9.2646)
27 Brismar K & Lewitt MS. The IGF and IGFBP system in insulin resistance
and diabetes mellitus. In IGF and Nutrition in Health and Disease,
ch 14, pp 251–270. Eds S Houston, J Holly & E Feldman. Totowa, NJ:
The Humana Press Inc, 2004.Received in final form 5 December 2013
Accepted 6 December 2013This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
